stoxline Quote Chart Rank Option Currency Glossary
  
Icosavax, Inc. (ICVX)
15.31  -0.14 (-0.91%)    02-16 16:00
Open: 15.4
High: 15.44
Volume: 8,556,852
  
Pre. Close: 15.45
Low: 15.28
Market Cap: 769(M)
Technical analysis
2024-03-08 4:52:41 PM
Short term     
Mid term     
Targets 6-month :  18.01 1-year :  18.19
Resists First :  15.42 Second :  15.57
Pivot price 15.34
Supports First :  15.17 Second :  12.62
MAs MA(5) :  15.31 MA(20) :  15.31
MA(100) :  12.08 MA(250) :  9.59
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  28.9 D(3) :  29.5
RSI RSI(14): 55.4
52-week High :  16.1 Low :  4.75
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ICVX ] has closed above bottom band by 34.4%. Bollinger Bands are 92.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.35 - 15.42 15.42 - 15.48
Low: 15.1 - 15.2 15.2 - 15.29
Close: 15.16 - 15.32 15.32 - 15.45
Company Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Headline News

Sun, 03 Mar 2024
Reviewing Avacta Group (OTCMKTS:AVCTF) & Icosavax (NASDAQ:ICVX) - Defense World

Tue, 20 Feb 2024
Icosavax Acquisition by AstraZeneca Leads to Delisting and Corporate Changes - TipRanks.com - TipRanks

Sun, 11 Feb 2024
Icosavax: Tender Offer With Contingent Value Right (NASDAQ:ICVX) - Seeking Alpha

Fri, 09 Feb 2024
Should You Sell Icosavax Inc (ICVX) in Biotechnology Industry? - InvestorsObserver

Fri, 26 Jan 2024
ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC ... - PR Newswire

Wed, 03 Jan 2024
ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 50 (M)
Shares Float 29 (M)
Held by Insiders 3.4 (%)
Held by Institutions 87.6 (%)
Shares Short 321 (K)
Shares Short P.Month 1,090 (K)
Stock Financials
EPS -2.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.63
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -26.8 %
Return on Equity (ttm) -42.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.06
Qtrly Earnings Growth 0 %
Operating Cash Flow -71 (M)
Levered Free Cash Flow -43 (M)
Stock Valuations
PE Ratio -6.96
PEG Ratio 0
Price to Book value 3.29
Price to Sales 0
Price to Cash Flow -10.76
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android